evaluating therapies in mds
Published 2 years ago • 38 plays • Length 3:38Download video MP4
Download video MP3
Similar videos
-
1:36
clinical trials evaluating novel agents in mds: select-mds-1
-
2:43
novel therapies in the future of mds treatment
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:41
the role of antibody-based therapies in mds treatment
-
1:41
an overview of the mds diagnosis pathway
-
1:58
therapy-related mds
-
1:45
what's to come for mds therapy?
-
49:25
myelodysplastic syndrome (mds) and anemia
-
20:12
mpn transformation to mds and aml: risk factors, therapy and outcomes
-
51:49
what's new in mds may 19 2021
-
1:17
evaluating response to treatment in patients with emd
-
1:48
immune therapy approaches in mds
-
0:55
the role of rna modifications in mds and aml
-
1:41
novel therapies for high-risk mds
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
1:17
exciting novel treatments being developed for mds
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
2:35
methods of optimizing transplantation in mds
-
2:25
master final analysis: quadruplet induction therapy, asct & mrd-adapted treatment cessation in ndmm
-
1:30
the prognostic value of patient-reported outcomes in mds
-
1:17
phase ii study of tosedostat in mds